EyePoint Pharmaceuticals ... (EYPT)
NASDAQ: EYPT
· Real-Time Price · USD
6.12
0.40 (6.99%)
At close: May 16, 2025, 3:59 PM
6.10
-0.33%
After-hours: May 16, 2025, 05:14 PM EDT
EyePoint Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|
| License And Collaboration Agreement Revenue | 38.5M | 28.33M | 16.96M | 13.88M | 12.05M |
| License And Collaboration Agreement Revenue Growth | +35.89% | +67.04% | +22.20% | +15.21% | n/a |
| Product Revenue | 3.16M | n/a | n/a | n/a | n/a |
| Product Revenue Growth | n/a | n/a | n/a | n/a | n/a |
| Royalty Revenue | 1.61M | n/a | n/a | n/a | n/a |
| Royalty Revenue Growth | n/a | n/a | n/a | n/a | n/a |
| Y U T I Q Product Revenue | 3.1M | n/a | n/a | n/a | n/a |
| Y U T I Q Product Revenue Growth | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 13.91M | 12.64M | 12.99M | 12.8M | 14.11M | 11.43M | 11.04M | 14.34M | 14.98M | 14.41M | 15.23M | 15.44M | 15.24M | 17.03M | 13.43M | 11.84M | 10.77M | 11.59M | 11.06M | 10.88M | 12.48M | 11.55M | 12.14M | 12.1M | 11.92M | 9.27M | 7.81M | 5.73M | 2.28M | 2.47M | 2.57M | 2.62M | 2.43M | 2.9M | 3.29M | 2.66M | 2.35M | 2.04M | 1.97M | 2.41M | 2.04M |
| Selling, General, and Administrative Revenue Growth | +10.06% | -2.73% | +1.52% | -9.26% | +23.39% | +3.61% | -23.07% | -4.24% | +3.94% | -5.37% | -1.37% | +1.31% | -10.49% | +26.75% | +13.43% | +9.92% | -7.02% | +4.72% | +1.69% | -12.85% | +8.11% | -4.90% | +0.36% | +1.49% | +28.63% | +18.71% | +36.20% | +151.29% | -7.73% | -3.89% | -1.98% | +8.16% | -16.34% | -11.72% | +23.68% | +13.21% | +14.83% | +3.81% | -18.37% | +18.13% | n/a |
| Research and Development Revenue | 58.57M | 43.37M | 29.54M | 29.82M | 30.14M | 17.95M | 17.36M | 15.73M | 13.62M | 15.54M | 11.16M | 12.99M | 9.95M | 8.92M | 8.5M | 5.61M | 5.48M | 5.21M | 4.09M | 3.28M | 4.85M | 4.13M | 3.48M | 3.96M | 3.8M | 4.18M | 6.23M | 4.76M | 3.33M | 4.27M | 3.82M | 4.21M | 3.32M | 3.17M | 4.18M | 4.1M | 3.07M | 3.72M | 3.48M | 3.2M | 3.34M |
| Research and Development Revenue Growth | +35.05% | +46.81% | -0.94% | -1.05% | +67.90% | +3.39% | +10.38% | +15.51% | -12.38% | +39.25% | -14.09% | +30.64% | +11.52% | +4.94% | +51.61% | +2.30% | +5.26% | +27.26% | +24.85% | -32.50% | +17.45% | +18.60% | -11.91% | +4.16% | -9.14% | -32.95% | +30.81% | +43.31% | -22.11% | +11.78% | -9.35% | +26.74% | +5.02% | -24.25% | +1.80% | +33.51% | -17.39% | +6.86% | +8.88% | -4.22% | n/a |
| Sales and Marketing Revenue | 35K | 51K | 24K | 50K | 6K | 185K | 479K | 5.29M | 5.74M | 5.92M | 6.02M | 6.88M | 6.69M | 7.81M | 7.37M | 6.66M | 5.66M | 5.81M | 5.27M | 6.09M | 8.13M | 7.4M | 7.78M | 7.28M | 7.31M | 4.53M | 3.65M | 1.51M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sales and Marketing Revenue Growth | -31.37% | +112.50% | -52.00% | +733.33% | -96.76% | -61.38% | -90.94% | -7.83% | -3.01% | -1.68% | -12.60% | +2.84% | -14.31% | +5.93% | +10.74% | +17.67% | -2.60% | +10.27% | -13.47% | -25.06% | +9.81% | -4.87% | +6.78% | -0.37% | +61.46% | +24.19% | +141.14% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |